Literature DB >> 15717177

Serum carnitine levels in patients with homozygous beta thalassemia: a possible new role for carnitine?

Vasileios Tsagris1, Georgia Liapi-Adamidou.   

Abstract

UNLABELLED: Carnitine (beta-hydroxy-gamma-trimethylaminobutyric acid) facilitates the transfer of activated long-chain fatty acids from the cytoplasm to the mitochondria, the site of their beta-oxidation. Carnitine deficiency results in a reduced usage of fatty acids in energy production and therefore the appearance of clinical symptoms such as myalgia and muscle weakness. In the present study, serum carnitine levels were measured in 45 children and 20 adults with homozygous beta thalassemia. A decrease in serum carnitine levels (total, free and acyl) was found, without any evidence of disorder in the process of mitochondrial beta-oxidation. The possible cause of this finding could be related to a reduced hepatic carnitine biosynthesis.
CONCLUSION: In patients with homozygous beta thalassemia, the reduction of serum carnitine levels might play an important role in the appearance of muscular dysfunction. It is possible that L : -carnitine administration in these patients might improve or even resolve the aforementioned symptom.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15717177     DOI: 10.1007/s00431-004-1590-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Deficiency of carnitine in cachectic cirrhotic patients.

Authors:  D Rudman; C W Sewell; J D Ansley
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Iron chelation with oral deferiprone in patients with thalassemia.

Authors:  M Stella; G Pinzello; A Maggio
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

3.  L-Carnitine treatment in beta thalassemia major.

Authors:  M A Yeşilipek; V Hazar; O Yegin
Journal:  Acta Haematol       Date:  1998-12       Impact factor: 2.195

4.  Muscle carnitine deficiency presenting as familial fatal cardiomyopathy.

Authors:  A A Colin; M Jaffe; Y Shapira; Z Ne'eman; A Gutman; S Korman
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

5.  A method for the determination of carnitine in the picomole range.

Authors:  G Cederblad; S Lindstedt
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

6.  The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features.

Authors:  G Karpati; S Carpenter; A G Engel; G Watters; J Allen; S Rothman; G Klassen; O A Mamer
Journal:  Neurology       Date:  1975-01       Impact factor: 9.910

7.  [Secondary diseases of the heart muscle and their differential diagnosis in childhood].

Authors:  L Sieverding; A A Schmaltz; D Hassberg; J Apitz; W Hort
Journal:  Wien Klin Wochenschr       Date:  1989-01-06       Impact factor: 1.704

8.  Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome.

Authors:  A G Engel; C Angelini
Journal:  Science       Date:  1973-03-02       Impact factor: 47.728

9.  Nearly fatal muscle carnitine deficiency with full recovery after replacement therapy.

Authors:  L D Prockop; W K Engel; A L Shug
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

10.  [Neurological and muscular manifestations of thalassemia major (author's transl)].

Authors:  F Mollica; M A Romeo; F di Gregorio; A Grasso; L Pavone
Journal:  Arch Fr Pediatr       Date:  1980-03
View more
  2 in total

Review 1.  Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategies.

Authors:  Giovanni Pagano; Annarita Aiello Talamanca; Giuseppe Castello; Mario D Cordero; Marco d'Ischia; Maria Nicola Gadaleta; Federico V Pallardó; Sandra Petrović; Luca Tiano; Adriana Zatterale
Journal:  Oxid Med Cell Longev       Date:  2014-05-04       Impact factor: 6.543

2.  Impaired acylcarnitine profile in transfusion-dependent beta-thalassemia major patients in Bangladesh.

Authors:  Suprovath Kumar Sarker; Md Tarikul Islam; Golam Sarower Bhuyan; Nusrat Sultana; Mst Noorjahan Begum; Mohammad Al Mahmud-Un-Nabi; Md Abdulla Al Noman Howladar; Tashmim Farhana Dipta; A K M Muraduzzaman; Syeda Kashfi Qadri; Tahmina Shirin; Salma Sadiya; Manzoor Hussain; Waqar Ahmed Khan; Sharif Akhteruzzaman; Syed Saleheen Qadri; Firdausi Qadri; Kaiissar Mannoor
Journal:  J Adv Res       Date:  2018-04-25       Impact factor: 10.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.